Weill Cornell and GHESKIO Awarded Renewed Funding for NIH Clinical Trails Unit for HIV Research in Haiti

Weill Cornell and GHESKIO were awarded a new 7-year cycle of support from the National Institutes of Health (NIH) for its clinical trials unit (CTU) in Port au Prince Haiti. Directed by Dr. Jean William Pape, Professor of Medicine at Weill Cornell, the GHESKIO CTU was established in 2006 and has been a global leader in the development and implementation of HIV clinical trials, specifically for treatment strategies for adults, pregnant women, adolescents and children. In this new funding cycle, GHESKIO will continue to advance the HIV scientific agenda with participation in studies on new therapeutic agents and antiretroviral therapy (ART) regimens including long-acting therapies, as well as effectiveness trials of behavioral, biomedical, and structural interventions to improve the proportion of people living with HIV who achieve viral suppression.  Trials of anti-tuberculosis therapy will also be conducted. Along with GHESKIO’s clinical services provided to over 100,000 people living with HIV each year, and its training of Haiti’s next generation of health care leaders, the research supported in the CTU supports and advances GHESKIO’s mission to deliver the highest standard of care to the most vulnerable populations in Haiti and serve as a model to other resource-limited settings.